Pregabalin

Phase 3Completed

0 watching 0 views this week📈 Rising

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Delirium

Conditions

Delirium, Pain

Trial Timeline

May 1, 2009 → Oct 1, 2011

NCT ID

NCT00819988

About Pregabalin

Pregabalin is a phase 3 stage product being developed by Pfizer for Delirium. The current trial status is completed. This product is registered under clinical trial identifier NCT00819988. Target conditions include Delirium, Pain.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (20)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01773993	Pre-clinical	Completed	Feb 1, 2013	Jul 1, 2017	Pain Associated With Fibromyalgia
NCT01603394	Approved	Terminated	Oct 1, 2012	Jun 1, 2013	Postherpetic Neuralgia
NCT01463306	Phase 3	Completed	Feb 21, 2012	Aug 22, 2019	Epilepsy, Partial Seizures
NCT01298466	Approved	Withdrawn	Feb 1, 2012	Feb 1, 2013	Low Back Pain
NCT01474772	Phase 3	Completed	Oct 1, 2011	Jul 1, 2013	Diabetic Peripheral Neuropathy
NCT01397006	Approved	Withdrawn	Sep 1, 2011	Mar 1, 2014	Fibromyalgia
NCT01020526	Approved	Completed	Sep 1, 2010	Jun 1, 2015	Fibromyalgia
NCT01202227	Phase 3	Completed	Sep 1, 2010	Mar 1, 2012	Spinal Cord Diseases
NCT01226667	Approved	Completed	Jul 1, 2010	Jul 1, 2012	Fibromyalgia
NCT00819988	Phase 3	Completed	May 1, 2009	Oct 1, 2011	Delirium
NCT00596466	Phase 3	Completed	Apr 1, 2008	Dec 1, 2011	Epilepsy
NCT00553280	Phase 3	Completed	Feb 1, 2008	Jan 1, 2010	Diabetic Neuropathy, Painful
NCT01061697	Approved	Completed	Jan 1, 2008	Apr 1, 2010	Cervical Spondylosis
NCT00891397	Pre-clinical	Terminated	Nov 1, 2007	Oct 1, 2010	Complex Regional Pain Syndromes
NCT00448916	Phase 3	Completed	May 1, 2007	Oct 1, 2013	Epilepsies, Partial
NCT00407797	Approved	Terminated	Mar 1, 2007	Aug 1, 2009	Partial Seizures
NCT00424372	Phase 3	Completed	Jan 12, 2007	Aug 19, 2008	Neuralgia, Postherpetic
NCT00407511	Approved	Completed	Jan 1, 2007	Jul 1, 2008	Diabetic Peripheral Neuropathic Pain (DPN)
NCT00346034	Phase 3	Completed	Dec 1, 2006	Feb 1, 2008	Fibromyalgia
NCT00843284	Pre-clinical	Completed	Sep 1, 2006	Mar 1, 2008	Neuropathic Pain

Competing Products

17 competing products in Delirium

See all competitors

Product	Company	Stage	Hype Score
Lemborexant 5 mg + Control (placebo) group	Eisai	Phase 2	52
Suvorexant + Placebo	Merck	Phase 3	77
Suvorexant 20 mg + Placebo	Merck	Phase 2	52
Rivastigmine + Placebo	Novartis	Approved	85
Rivastigmine prevention of delirium	Novartis	Phase 3	77
Rivastigmine transdermal patch + placebo patch	Novartis	Phase 3	77
Rivastigmine Patch	Novartis	Approved	85
Dexmedetomidine + Placebo	Pfizer	Phase 3	76
Parecoxib	Pfizer	Approved	84
Dexmedetomidine + Placebo	Pfizer	Phase 3	76
Dexmedetomidine + Midazolam	Pfizer	Phase 3	76
Propofol + Dexmedetomidine	Pfizer	Pre-clinical	22
Dexmedetomidine + Saline placebo	Pfizer	Phase 2/3	64
Cyclopofol + Propofol	Haisco Pharmaceutical Group	Approved	82
Dexmedetomidine + Sodium chloride 0.9%	Baxter	Phase 3	74
Dexmedetomidine Hydrochloride Group	Brain Biotech	Approved	77
Dexmedetomidine sublingual film	BioXcel Therapeutics	Phase 2	44

Other Products from Pfizer